ClinicalTrials.gg
CompletedNCT02917200Updated Sep 12, 2017

Safety and Efficacy Study of Different DAV132 Dose Regimens in Healthy Volunteers

A Phase 1 interventional study of Moxifloxacin and DAV132 in Healthy Subjects, sponsored by Da Volterra. Completed at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-12.

Sponsored by Da Volterra · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2016, registered Sep 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate whether different DAV132 dose regimens are safe and effective for capturing fecal residues of moxifloxacin in healthy volunteers.

Read the detailed description

The aim of the study is to evaluate the performances of different DAV132 dose regimens in healthy volunteers:

  • To capture antibiotic residues in the colon without interfering with its systemic pharmacokinetics.
  • To prevent antibiotic-induced changes of the intestinal microbiota. In addition, the security of DAV132 given at different dose regimens during 7 days will be evaluated.

This is a prospective, randomized, controlled, repeated doses, 12 parallel groups, open-label study, blinded to analytical and microbiological evaluations.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Da Volterra is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults (males and females), able to read and write, aged from 18 to 60 years old inclusive.
  2. (BMI) 18.5 - 30 kg/m² inclusive.
  3. Considered as healthy individuals according to a comprehensive clinical assessment (detailed medical history and full physical examination).
  4. Normal vital signs after 10-min rest in supine position: systolic blood pressure 95 - 140 mmHg inclusive, diastolic blood pressure 45 - 90 mmHg inclusive and heart rate (pulse rate) 50 - 100 bpm inclusive. Out of range values can be accepted if judged clinically non relevant by the Investigator.
  5. Normal 12-lead after 10-min rest in supine position: PR interval 120 - 220 msec exclusive, QRS complex \<120 msec, and \<430 msec if male or \<450 msec if female.
  6. Normal hematology and blood biochemistry test results. Out of range values can be accepted if judged clinically non relevant by the Investigator excepted for potassium and magnesium for which normal values are required.
  7. Normal digestive transit, with at least one daily stool.
  8. Females participating in the study:

    • either must be of non-child bearing potential (surgically sterilized at least 3 months prior to inclusion, or ). Menopause is defined as being over 60 years of age, or between 45 and 60 years of age and being amenorrheic for at least 2 years with plasma FSH levels >30 IU/L;
    • or must have a negative pregnancy test and be not breastfeeding at screening, and must use abstinence or a double method during the treatment period and for an additional period of 2 weeks after the end of treatment. The accepted double contraception methods include the use of a highly effective method of birth control (intrauterine device or hormonal contraception) in addition to one of the following contraceptive options: (1) condom, (2) diaphragm or cervical/vault cap, (3) spermicide.
  9. Having given and signed the written study prior to undertake any study-related procedure.
  10. Covered by the French health insurance system.

Exclusion criteria

Exclusion Criteria:

Criteria related to the healthy status

  1. Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, bone and joint, muscular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease; or signs of acute illness.
  2. Any history of relevant gastrointestinal disorders within three months prior to inclusion.
  3. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for each event, more than twice a month). Subject suffering from migraine on D1 will be excluded.
  4. Presence or history of drug , or allergic disease diagnosed and treated by a physician.

    Criteria specific to the study

  5. to fluoroquinolones, or risk factors for adverse effects associated to fluoroquinolones as defined in the moxifloxacin Summary of Product Characteristics, and other than those already included into the inclusion/exclusion criteria: known hypersensitivity to fluoroquinolones, history of tendinopathy associated with fluoroquinolones, risk factor for tendinopathy / known tendon disorder, pregnancy, breast feeding, known history of myasthenia gravis, known history of / risk factors for prolongation (including close family history of arrhythmic disorders). Subjects with a family history of, or actual glucose-6-phosphate dehydrogenase (G6PDH) deficiency should be excluded. Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should be excluded.
  6. Contraindications to charcoal, or risk factors for adverse events associated to charcoal other than those already included into the inclusion/exclusion criteria: known hypersensitivity to charcoal, risk of gastrointestinal obstruction, perforation or hemorrhage, recent digestive tract surgery.
  7. Fecal colonization by C. difficile.
  8. Recent history of hospitalization (within the last 3 months).
  9. Any antibiotic administration within the last 3 months.
  10. Any vaccination within the last 28 days.
  11. Blood donation, regardless of the volume, within 2 months before inclusion and during the study.
  12. Any previous administration of medication and any previous intake of herbal products known to interfere with drug metabolism such as St John's Wort within the last 14 days, with the exception of hormonal or menopausal hormone replacement therapy or paracetamol.

    Criteria associated with addiction

  13. History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day).
  14. Smoking more than 5 cigarettes or equivalent per day (including nicotine-delivering devices such as patches, gums and electronic cigarettes), unable to stop smoking during the study.
  15. Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day).
  16. Positive result on urine drug screen (amphetamines / methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
  17. Positive alcohol test. Administrative criteria
  18. Any subject who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
  19. Any subject in the exclusion period of a previous biomedical research according to national law, and participation to any other clinical trial simultaneously.
  20. Any subject who cannot be contacted in case of emergency.
  21. Any subject who belongs to the Investigating Center staff.
  22. Subject of legal age unable to give consent
  23. Subject deprived of liberty by judicial or administrative decision
  24. Subject of legal age under legal protection.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Active comparator
    MOX + CTRL

    Moxifloxacin, 400 mg/day oad, 5 days + Negative control, tid, 7 days

    Drug: Moxifloxacin · Other: Negative control

  • Experimental
    MOX + DAV132 7.5 g tid

    Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g tid, 7 days

    Drug: Moxifloxacin · Device: DAV132

  • Experimental
    MOX + DAV132 7.5 g bid

    Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g bid, 7 days

    Drug: Moxifloxacin · Device: DAV132

  • Experimental
    MOX + DAV132 5 g tid

    Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g tid, 7 days

    Drug: Moxifloxacin · Device: DAV132

  • Experimental
    MOX + DAV132 5 g bid

    Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g bid, 7 days

    Drug: Moxifloxacin · Device: DAV132

  • Experimental
    MOX + DAV132 3.3 g tid

    Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3.3 g tid, 7 days

    Drug: Moxifloxacin · Device: DAV132

  • Experimental
    MOX + DAV132 3 g bid

    Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3 g bid, 7 days

    Drug: Moxifloxacin · Device: DAV132

  • Experimental
    MOX + DAV132 2 g tid

    Moxifloxacin, 400 mg/day oad, 5 days + DAV132 2 g tid, 7 days

    Drug: Moxifloxacin · Device: DAV132

  • Experimental
    MOX + DAV132 1.5 g bid

    Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1.5 g bid, 7 days

    Drug: Moxifloxacin · Device: DAV132

  • Experimental
    MOX + DAV132 1 g tid

    Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g tid, 7 days

    Drug: Moxifloxacin · Device: DAV132

  • Experimental
    MOX + DAV132 1 g bid

    Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g bid, 7 days

    Drug: Moxifloxacin · Device: DAV132

  • Other
    CTRL

    Negative control, tid, 7 days

    Other: Negative control

Interventions

  • Oral route

  • DeviceDAV132

    Oral route

  • OtherNegative control

    Oral route

06

What researchers measure

Primary outcomes

  1. Area under the curve of free moxifloxacin fecal concentrations from D1 to D16 (AUC D1-D16)

    Time frame: over 16 days after treatment start

Secondary outcomes

  1. Bacterial diversity of the intestinal microbiota (16S rDNA profiling)

    Time frame: over 37 days after treatment start

  2. Area under the curve of moxifloxacin plasma concentrations from 0 to 24 hours (AUC0-24h) on D1 and D5

    Time frame: over 5 days after treatment start

  3. Maximum moxifloxacin plasma concentrations (Cmax) on D1 and D5

    Time frame: over 5 days after treatment start

  4. Number of adverse events and percentage of subjects with at least one adverse event

    Time frame: over 37 days after treatment start

  5. Number of subjects with samples positive for treatment-emergent quinolone / fluoroquinolone-resistant Enterobacteriaceae

    Time frame: over 37 days after treatment start

  6. Occurrence of Clostridium difficile infection, evaluated by identification of C. difficile in diarrheic stools

    Time frame: over 37 days after treatment start

07

Study locations

1 site
  • Eurofins Optimed
    Gières, 38610, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Dec 2016, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2016
First posted
Sep 28, 2016
StartActual
May 11, 2016
Primary completionActual
Dec 2, 2016
CompletionActual
Dec 2, 2016
Last update
Sep 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02917200
Lead sponsor
Da Volterra
Responsible party
Sponsor
First posted
Sep 28, 2016
Start date
May 11, 2016
Primary completion
Dec 2, 2016
Completion
Dec 2, 2016
Last update
Sep 12, 2017

Study contacts

Yves Donazzolo
principal investigator · Eurofins Optimed

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion